Levosimendan Kalceks (Levosimendan)

• Levosimendan is employed in the management of acute cardiac failure syndromes, acting on the heart’s contractile machinery and vascular tone.
• Acute decompensated heart failure: improves cardiac output and relieves symptoms of congestion.
• Severe left ventricular systolic dysfunction: provides inotropic support during acute episodes.
• Cardiogenic shock (when conventional therapy is insufficient): offers temporary hemodynamic stabilization.

• Levosimendan binds to troponin C in cardiac myocytes, increasing its sensitivity to calcium and thereby enhancing contractile force without raising intracellular calcium levels. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing arterial and venous dilation, which reduces preload and afterload and improves overall cardiac performance.

Levosimendan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Headache: mild to moderate intensity.
• Hypotension: transient blood pressure drop.
• Nausea: occasional gastrointestinal upset.
• Dizziness: related to blood pressure changes.
• Tachycardia: increased heart rate.
• Flushing: warm sensation of skin.

Serious or Rare Side Effects

• Ventricular arrhythmias: potentially life‑threatening rhythm disturbances.
• Myocardial ischemia: reduced blood flow to heart muscle.
• Severe hypotension: marked drop in blood pressure requiring intervention.
• Allergic reactions: rash, bronchospasm, or anaphylaxis.
• Pulmonary edema: fluid accumulation in lungs.
• Liver enzyme elevation: abnormal hepatic function tests.

Levosimendan requires careful clinical monitoring and specific safety considerations before and during therapy.

• Cardiovascular monitoring: observe blood pressure and heart rhythm continuously.
• Electrolyte balance: correct potassium and magnesium levels to reduce arrhythmia risk.
• Renal function: assess creatinine clearance, adjust therapy if impairment present.
• Hepatic impairment: use with caution in patients with liver disease.
• Concomitant vasodilators: avoid excessive hypotension when combined.
• Pregnancy category unknown: avoid use unless benefits outweigh potential risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid)

• Other potent vasodilators: may cause severe hypotension.
• Concurrent inotropes (e.g., dobutamine): additive cardiac stress.
• Phosphodiesterase inhibitors: increase risk of hypotension.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may blunt inotropic response.
• ACE inhibitors or ARBs: additive blood pressure lowering effect.
• Diuretics: potential electrolyte disturbances.
• Calcium channel blockers: may affect vascular tone.
• Anticoagulants: monitor for bleeding if hypotension occurs.